Cargando…

A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer

Lymph node metastasis (LNM) of colorectal cancer (CRC) is an important factor for both prognosis and treatment. Given the deficiencies of conventional tests, we aim to discover novel DNA methylation markers to efficiently identify LNM status of CRC. In this study, genome-wide methylation sequencing...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yingdian, Xue, Wenyuan, Liu, Zefeng, Chen, Shang, Wang, Jun, Peng, Quanzhou, Xu, Linhao, Liu, Xin, Cui, Chunhui, Fan, Jian-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614158/
https://www.ncbi.nlm.nih.gov/pubmed/36313642
http://dx.doi.org/10.3389/fonc.2022.1000823
_version_ 1784820132311203840
author Yu, Yingdian
Xue, Wenyuan
Liu, Zefeng
Chen, Shang
Wang, Jun
Peng, Quanzhou
Xu, Linhao
Liu, Xin
Cui, Chunhui
Fan, Jian-Bing
author_facet Yu, Yingdian
Xue, Wenyuan
Liu, Zefeng
Chen, Shang
Wang, Jun
Peng, Quanzhou
Xu, Linhao
Liu, Xin
Cui, Chunhui
Fan, Jian-Bing
author_sort Yu, Yingdian
collection PubMed
description Lymph node metastasis (LNM) of colorectal cancer (CRC) is an important factor for both prognosis and treatment. Given the deficiencies of conventional tests, we aim to discover novel DNA methylation markers to efficiently identify LNM status of CRC. In this study, genome-wide methylation sequencing was performed in a cohort (n=30) using fresh CRC tissue to discover differentially methylated markers. These markers were subsequently validated with fluorescence quantitative PCR in a cohort (n=221), and the optimal marker was compared to conventional diagnostic methods. Meanwhile, immunohistochemistry was used to verify the effectiveness of the antibody corresponding to this marker in a cohort (n=56). LBX2 achieved an AUC of 0.87, specificity of 87.3%, sensitivity of 75.7%, and accuracy of 81.9%, which outperformed conventional methods including imaging (CT, PET-CT) with an AUC of 0.52, CA199 with an AUC of 0.58, CEA with an AUC of 0.56. LBX2 was also superior to clinicopathological indicators including the depth of tumor invasion and lymphatic invasion with an AUC of 0.61and 0.63 respectively. Moreover, the AUC of LBX2 antibody was 0.84, which was also better than these conventional methods. In conclusion, A novel methylation marker LBX2 could be used as a simple, cost-effective, and reliable diagnostic method for LNM of CRC.
format Online
Article
Text
id pubmed-9614158
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96141582022-10-29 A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer Yu, Yingdian Xue, Wenyuan Liu, Zefeng Chen, Shang Wang, Jun Peng, Quanzhou Xu, Linhao Liu, Xin Cui, Chunhui Fan, Jian-Bing Front Oncol Oncology Lymph node metastasis (LNM) of colorectal cancer (CRC) is an important factor for both prognosis and treatment. Given the deficiencies of conventional tests, we aim to discover novel DNA methylation markers to efficiently identify LNM status of CRC. In this study, genome-wide methylation sequencing was performed in a cohort (n=30) using fresh CRC tissue to discover differentially methylated markers. These markers were subsequently validated with fluorescence quantitative PCR in a cohort (n=221), and the optimal marker was compared to conventional diagnostic methods. Meanwhile, immunohistochemistry was used to verify the effectiveness of the antibody corresponding to this marker in a cohort (n=56). LBX2 achieved an AUC of 0.87, specificity of 87.3%, sensitivity of 75.7%, and accuracy of 81.9%, which outperformed conventional methods including imaging (CT, PET-CT) with an AUC of 0.52, CA199 with an AUC of 0.58, CEA with an AUC of 0.56. LBX2 was also superior to clinicopathological indicators including the depth of tumor invasion and lymphatic invasion with an AUC of 0.61and 0.63 respectively. Moreover, the AUC of LBX2 antibody was 0.84, which was also better than these conventional methods. In conclusion, A novel methylation marker LBX2 could be used as a simple, cost-effective, and reliable diagnostic method for LNM of CRC. Frontiers Media S.A. 2022-10-14 /pmc/articles/PMC9614158/ /pubmed/36313642 http://dx.doi.org/10.3389/fonc.2022.1000823 Text en Copyright © 2022 Yu, Xue, Liu, Chen, Wang, Peng, Xu, Liu, Cui and Fan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yu, Yingdian
Xue, Wenyuan
Liu, Zefeng
Chen, Shang
Wang, Jun
Peng, Quanzhou
Xu, Linhao
Liu, Xin
Cui, Chunhui
Fan, Jian-Bing
A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer
title A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer
title_full A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer
title_fullStr A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer
title_full_unstemmed A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer
title_short A novel DNA methylation marker to identify lymph node metastasis of colorectal cancer
title_sort novel dna methylation marker to identify lymph node metastasis of colorectal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614158/
https://www.ncbi.nlm.nih.gov/pubmed/36313642
http://dx.doi.org/10.3389/fonc.2022.1000823
work_keys_str_mv AT yuyingdian anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT xuewenyuan anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT liuzefeng anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT chenshang anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT wangjun anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT pengquanzhou anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT xulinhao anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT liuxin anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT cuichunhui anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT fanjianbing anoveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT yuyingdian noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT xuewenyuan noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT liuzefeng noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT chenshang noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT wangjun noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT pengquanzhou noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT xulinhao noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT liuxin noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT cuichunhui noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer
AT fanjianbing noveldnamethylationmarkertoidentifylymphnodemetastasisofcolorectalcancer